Bank Of New York Mellon Corp Inhibrx, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$18.45 - $27.14 $1.94 Million - $2.86 Million	105,377 New	105,377 $1.99 Billion
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $2.17 Million - $3.58 Million	107,514 New	107,514 $2.65 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $164,459 - $351,215	14,202 Added 17.16%	96,949 $1.74 Million
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $29,198 - $86,566	-3,427 Reduced 3.98%	82,747 $938,000
Q1 2022 May 11, 2022	BUY	$19.89 - $43.18 $20,228 - $43,914	1,017 Added 1.19%	86,174 $1.92 Million
Q4 2021 Feb 11, 2022	SELL	$26.75 - $46.02 $25,091 - $43,166	-938 Reduced 1.09%	85,157 $3.72 Million
Q3 2021 Nov 12, 2021	BUY	$25.18 - $37.81 $653,043 - $980,602	25,935 Added 43.11%	86,095 $2.87 Million
Q2 2021 Aug 11, 2021	BUY	$14.69 - $27.52 $476,866 - $893,354	32,462 Added 117.2%	60,160 $1.66 Million
Q1 2021 May 13, 2021	SELL	$16.27 - $41.26 $1,919 - $4,868	-118 Reduced 0.42%	27,698 $555,000
Q4 2020 Feb 09, 2021	BUY	$15.96 - $50.0 $443,943 - $1.39 Million	27,816 New	27,816 $917,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.